{"entity":{"id":"trastuzumab-biosimilars","kind":"drug","name":"Trastuzumab biosimilars","aka":[],"tldr":"Near-identical copies of Herceptin, approved since 2017, that cut the price of HER2 treatment and widened access worldwide.","summary":"Six US-approved biosimilars (first: Ogivri, December 2017) with equivalence shown on pCR or ORR endpoints; WHO prequalification (2019) enabled low- and middle-income access. Biosimilar uptake exceeds 80% of trastuzumab volume in the US and EU; they are the trastuzumab component of many chemotherapy-antibody regimens and control arms.","status":"approved","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Biosimilar","links":[{"label":"FDA label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20biosimilars"}],"tags":[],"related":[],"cancers":["breast-her2-positive","gastric"],"sections":[],"technologies":["monoclonal-antibody"],"targets":["her2"],"drugs":[],"companies":["organon"],"institutions":[],"pathways":[],"terms":["biosimilar"],"trials":["nct01275677","nct00769379","nct02003209"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Ogivri, Herzuma, Kanjinti, Trazimera, Ontruzant, Hercessi","modality":"Biosimilar monoclonal antibody (anti-HER2)","mechanism":"Same amino acid sequence and mechanism as trastuzumab; analytical and clinical equivalence demonstrated.","approvals":[{"region":"US","year":2017,"indication":"First trastuzumab biosimilar (Ogivri); all trastuzumab indications"},{"region":"EU","year":2017,"indication":"Ontruzant, first EU trastuzumab biosimilar"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/trastuzumab-biosimilars/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"biocon","kind":"company","name":"Biocon","route":"/companies/biocon/"},{"id":"biocon-biologics","kind":"company","name":"Biocon Biologics","route":"/companies/biocon-biologics/"},{"id":"organon","kind":"company","name":"Organon & Co.","route":"/companies/organon/"},{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"},{"id":"viatris","kind":"company","name":"Viatris","route":"/companies/viatris/"}],"term":[{"id":"bpcia","kind":"term","name":"Biologics Price Competition and Innovation Act 2010","route":"/terms/bpcia/"},{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/"}],"trial":[{"id":"nct01275677","kind":"trial","name":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","route":"/trials/nct01275677/"},{"id":"nct02003209","kind":"trial","name":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","route":"/trials/nct02003209/"},{"id":"nct04425018","kind":"trial","name":"MARGetuximab Or Trastuzumab (MARGOT)","route":"/trials/nct04425018/"},{"id":"nct00769379","kind":"trial","name":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","route":"/trials/nct00769379/"}],"person":[{"id":"mazumdar-shaw-kiran","kind":"person","name":"Kiran Mazumdar-Shaw","route":"/people/mazumdar-shaw-kiran/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"}],"idea":[{"id":"idea-cost-biosimilar-default-substitution","kind":"idea","name":"Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab","route":"/ideas/idea-cost-biosimilar-default-substitution/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}